The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis.

Authors: Polak, Paul E  Lin, Shao Xia  Pelligrino, Dale  Feinstein, Douglas L 
Citation: Polak PE, etal., J Neuroimmunol. 2014 Nov 15;276(1-2):135-41. doi: 10.1016/j.jneuroim.2014.09.004. Epub 2014 Sep 16.
Pubmed: (View Article at PubMed) PMID:25242632
DOI: Full-text: DOI:10.1016/j.jneuroim.2014.09.004

Reduced levels of noradrenaline (NA) in CNS of multiple sclerosis patients could be due to metabolism by catechol-O-methyltransferase (COMT). In mice immunized with myelin oligodendrocyte glycoprotein peptide, the BBB-permeable COMT inhibitor dinitrocatechol (DNC) reduced clinical signs, while entacapone, a non-BBB-permeable inhibitor, had no effect. Spinal cord NA levels were slightly increased by DNC, and there was an inverse correlation between NA levels and average clinical signs. Spinal cord COMT mRNA levels were not increased during EAE, but were found increased in the frontal cortex of MS patients. These results suggest that COMT inhibitors could provide benefit to MS patients.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 13450949
Created: 2017-11-14
Species: All species
Last Modified: 2017-11-14
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.